Prevalence and crude ORs of LBW, PB and SGA according to the average daily dose of ICS* and LABA use during pregnancy
| LBW | PB | SGA | ||||
|---|---|---|---|---|---|---|
| n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | |
| LABA | ||||||
| None | 515 (7.7) | Reference | 641 (9.5) | Reference | 895 (13.3) | Reference |
| LABA | 55 (8.5) | 1.05 (0.79 to 1.41) | 63 (9.7) | 0.99 (0.75 to 1.31) | 98 (15.1) | 1.13 (0.90 to 1.42) |
| Daily ICS dose (μg/day) | ||||||
| None | 239 (7.5) | Reference | 305 (9.6) | Reference | 404 (12.7) | Reference |
| >0–62.5 | 102 (6.2) | 0.80 (0.63 to 1.02) | 133 (8.1) | 0.81 (0.66 to 1.00) | 201 (12.2) | 0.95 (0.79 to 1.13) |
| >62.5–125 | 106 (8.1) | 1.10 (0.87 to 1.40) | 130 (10.0) | 1.06 (0.86 to 1.32) | 190 (14.6) | 1.18 (0.98 to 1.42) |
| >125–250 | 64 (9.3) | 1.24 (0.93 to 1.65) | 73 (10.6) | 1.14 (0.87 to 1.49) | 99 (14.4) | 1.17 (0.92 to 1.48) |
| >250–500 | 41 (10.0) | 1.34 (0.95 to 1.89) | 45 (11.0) | 1.20 (0.87 to 1.66) | 68 (16.6) | 1.35 (1.01 to 1.79) |
| >500 | 18 (12.2) | 1.66 (1.01 to 2.73) | 18 (12.2) | 1.13 (0.65 to 1.97) | 31 (20.9) | 1.80 (1.19 to 2.71) |
*Fluticasone equivalent, μg/day.
ICS, inhaled corticosteroid; LABA, long-acting B2-agonist; LBW, low birth weight; PB, preterm birth; SGA, small for gestational age.